Literature DB >> 3549811

Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata.

V C Fiedler-Weiss.   

Abstract

Topical minoxidil solution can induce hair regrowth in alopecia areata. A dose-response effect was demonstrated when 48 patients treated with topical 1% minoxidil were compared with 47 patients treated with topical 5% minoxidil. A total of 66 patients were enrolled, 26 of them participating in both study groups. Patients with extensive (75% or greater) scalp hair loss showed a response rate of 38%, defined as terminal hair regrowth, with 1% minoxidil versus an 81% response rate with 5% minoxidil. The current 2% formulation is most likely to elicit cosmetically acceptable regrowth in those with patchy alopecia areata. Occlusion of the treated area appears to be necessary to achieve and maintain maximum results. Nonresponders are most likely to be found among those with the most extensive scalp hair loss. No other clinical features correlate with response to treatment. However, a finding of increased T cell blastogenesis before treatment may predict response. In patients with severe alopecia areata, hair loss generally recurs after treatment is stopped and may recur during treatment. Systemic absorption of topically applied and occluded minoxidil solutions (1% and 5%) was minimal; no clinically significant changes in blood pressure, weight, cardiovascular status, electrocardiogram, electrolytes, complete blood count, or urinalysis were seen. Mild local irritation occurred, and two of the 66 patients developed allergic contact dermatitis to minoxidil, as confirmed by patch tests.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3549811     DOI: 10.1016/s0190-9622(87)80003-8

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  11 in total

Review 1.  Alopecia areata: Part 2: treatment.

Authors:  Frank Spano; Jeff C Donovan
Journal:  Can Fam Physician       Date:  2015-09       Impact factor: 3.275

Review 2.  Treatments for androgenetic alopecia and alopecia areata: current options and future prospects.

Authors:  V M Meidan; E Touitou
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  Beneficial Extracardiac Effects of Cardiovascular Medications.

Authors:  Asra K Butt; Jay Patel; Hamid Shirwany; Qasim Mirza; Jonathan Hoover; Rami N Khouzam
Journal:  Curr Cardiol Rev       Date:  2022

4.  Alopecia areata: a new treatment plan.

Authors:  Adel Alsantali
Journal:  Clin Cosmet Investig Dermatol       Date:  2011-07-22

5.  Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population.

Authors:  Shahin Aghaei
Journal:  BMC Dermatol       Date:  2005-05-26

6.  Role of platelet-rich plasma in chronic alopecia areata: Our centre experience.

Authors:  Sukhbir Singh
Journal:  Indian J Plast Surg       Date:  2015 Jan-Apr

7.  Production and characterization of a new antibacterial peptide obtained from Aeribacillus pallidus SAT4.

Authors:  Syed Aun Muhammad; Safia Ahmed
Journal:  Biotechnol Rep (Amst)       Date:  2015-09-21

8.  Glibenclamide reverses cardiovascular abnormalities of Cantu syndrome driven by KATP channel overactivity.

Authors:  Conor McClenaghan; Yan Huang; Zihan Yan; Theresa M Harter; Carmen M Halabi; Rod Chalk; Attila Kovacs; Gijs van Haaften; Maria S Remedi; Colin G Nichols
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

9.  Current treatment strategies in pediatric alopecia areata.

Authors:  Etienne Wang; Joyce Ss Lee; Mark Tang
Journal:  Indian J Dermatol       Date:  2012-11       Impact factor: 1.494

Review 10.  Minoxidil and its use in hair disorders: a review.

Authors:  Poonkiat Suchonwanit; Sasima Thammarucha; Kanchana Leerunyakul
Journal:  Drug Des Devel Ther       Date:  2019-08-09       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.